Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stressgen Bioreagents was a leading provider of high-quality research reagents, specializing in the fields of cellular stress, heat shock proteins (HSPs), and molecular chaperones. Founded as a division of Stressgen Biotechnologies, the company developed an extensive catalog of antibodies, proteins, and ELISA kits used globally in academic and pharmaceutical research. In 2006, the bioreagents business was acquired by Assay Designs for $16 million, which was subsequently acquired by Enzo Life Sciences in 2009. Today, the Stressgen product line continues to be marketed under the Enzo Life Sciences portfolio, supporting research in oncology, inflammation, and neurobiology. The company was instrumental in providing the scientific community with tools to study protein folding and the cellular response to environmental stress.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stressgen Bioreagents.